The survivin:fas ratio in pediatric renal tumors
- PMID: 11150435
- DOI: 10.1053/jpsu.2001.20000
The survivin:fas ratio in pediatric renal tumors
Abstract
Background/purpose: Apoptosis factors inducing or preventing cell death may govern the behavior of certain tumors. Fas is a pro-apoptotic receptor that induces cell death when bound by its ligand and is expressed at greater levels in pediatric renal tumors of good prognosis. Survivin is a novel inhibitor of apoptosis that is expressed in a cell cycle-dependent manner and is abundantly expressed in several tumors of unfavorable histology. This study evaluates the expression of survivin, as well as the prognostic value of the survivin:fas ratio in various types and stages of pediatric renal tumors.
Methods: Multiple apoptosis mRNA species were quantified by Rnase protection assay (RPA) in 32 pediatric renal tumors and adjacent normal kidney specimens before chemotherapy: Wilms' tumor (WT), n = 9; clear cell sarcoma (CCS), n = 4; rhabdoid tumor of the kidney (RTK), n = 5; mesoblastic nephroma (MN), n = 3 and normal kidney, n = 11. Western Blot and immunocytochemistry were used to confirm survivin protein expression in a selective specimen survey. Follow-up data were obtained on patient outcomes, and antiapoptotic to proapoptotic ratios were calculated and correlated with clinical recurrence of disease.
Results: Pediatric renal tumors express greater levels of both pro- and antiapoptotic factors than normal kidney. Survivin and fas appeared to be expressed differentially in the tumor specimens sampled. Five of 10 (50%) tumors that went on to recur expressed survivin, whereas survivin was present in only 2 of 11 (18%) nonrecurrent tumors. Conversely, only 2 of 10 (20%) tumors that recurred were fas positive, whereas 5 of 11 (45%) tumors that did not recur expressed fas. The mean survivin:fas ratio was significantly greater in the 10 tumors that went on to recur after treatment (4 RTK, 3 CCS, 3 WT), than in tumors not recurring (2.16+/-1.4 v 1.0+/-1.07; P =.01, Kruskal-Wallis test). The positive predictive value of tumor recurrence was 85.7% (CI: 42.1%, 99.6%) and the negative predictive value was 71.4% (CI: 41.9%, 91.6%) when a cutoff ratio of 1.6 was considered.
Conclusions: The survivin:fas mRNA ratio is of prognostic value in its ability to predict recurrent disease in children undergoing treatment for pediatric renal tumors. In this series, a ratio of greater than 1.6 predicted recurrent disease with a high probability irrespective of clinical stage or pathologic type. Determining the survivin:fas ratio may guide treatment, follow-up and counseling of patients with pediatric renal tumors.
Similar articles
-
The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma.J Pediatr Surg. 2001 Dec;36(12):1785-91. doi: 10.1053/jpsu.2001.28839. J Pediatr Surg. 2001. PMID: 11733907
-
The survivin:Fas ratio is predictive of recurrent disease in neuroblastoma.J Pediatr Surg. 2002 Mar;37(3):507-11. doi: 10.1053/jpsu.2002.30857. J Pediatr Surg. 2002. PMID: 11877677
-
Survivin expression predicts early recurrence in early-stage breast cancer.Anticancer Res. 2007 Jul-Aug;27(4C):2803-8. Anticancer Res. 2007. PMID: 17695451
-
[Solid tumors in children. New advances and the importance of histological sub-classifications. I. Renal tumors in children].Ann Pathol. 1988;8(2):114-25. Ann Pathol. 1988. PMID: 2840918 Review. French.
-
Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology.Leuk Lymphoma. 2002 Dec;43(12):2249-55. doi: 10.1080/1042819021000039956. Leuk Lymphoma. 2002. PMID: 12613509 Review.
Cited by
-
Remaining Challenges in the Treatment of Relapsed Wilms Tumor: Children's Oncology Group and International Society of Paediatric Oncology Perspectives.Pediatr Blood Cancer. 2025 Aug;72(8):e31790. doi: 10.1002/pbc.31790. Epub 2025 May 14. Pediatr Blood Cancer. 2025. PMID: 40369656
-
Serum and urine survivin levels in breast cancer.Med Oncol. 2006;23(3):335-9. doi: 10.1385/mo:23:3:335. Med Oncol. 2006. PMID: 17018890
-
Destined to Die: Apoptosis and Pediatric Cancers.Cancers (Basel). 2019 Oct 23;11(11):1623. doi: 10.3390/cancers11111623. Cancers (Basel). 2019. PMID: 31652776 Free PMC article. Review.
-
Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.Leukemia. 2012 Feb;26(2):271-9. doi: 10.1038/leu.2011.199. Epub 2011 Aug 16. Leukemia. 2012. PMID: 21844871 Free PMC article.
-
Prognostic importance of survivin in breast cancer.Br J Cancer. 2003 Apr 7;88(7):1077-83. doi: 10.1038/sj.bjc.6600776. Br J Cancer. 2003. PMID: 12671708 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous